Myriad Genetics (MYGN) PT Up to $46 at Leerink Partners After Solid Q1
Tweet Send to a Friend
Leerink Partners analyst Dan Leonard lifted his price target on Myriad Genetics (NASDAQ: MYGN) to $46.00 (from $37.00) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
